Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1979 1
1986 1
1987 1
1989 1
1991 2
1992 9
1993 4
1994 2
1995 4
1996 2
1997 6
1998 7
1999 10
2000 2
2001 4
2002 8
2003 10
2004 6
2005 5
2006 6
2007 8
2008 4
2009 5
2010 3
2011 9
2012 3
2013 3
2014 1
2015 2
2016 2
2017 1
2019 2
2020 2
2021 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

130 results

Results by year

Filters applied: . Clear all
Page 1
Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris.
Lucky AW, Henderson TA, Olson WH, Robisch DM, Lebwohl M, Swinyer LJ. Lucky AW, et al. J Am Acad Dermatol. 1997 Nov;37(5 Pt 1):746-54. doi: 10.1016/s0190-9622(97)70112-9. J Am Acad Dermatol. 1997. PMID: 9366821 Clinical Trial.
OBJECTIVE: Our purpose was to evaluate the efficacy of a triphasic, combination OC (ORTHO TRI-CYCLEN [Ortho-McNeil Pharmaceutical, Raritan, N.J.], norgestimate/ethinyl estradiol) compared with placebo in the treatment of moderate acne vulgaris. ...CONCLUSION: An OC contain …
OBJECTIVE: Our purpose was to evaluate the efficacy of a triphasic, combination OC (ORTHO TRI-CYCLEN [Ortho-McNeil Pharmaceutical, Raritan, …
Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial.
Redmond GP, Olson WH, Lippman JS, Kafrissen ME, Jones TM, Jorizzo JL. Redmond GP, et al. Obstet Gynecol. 1997 Apr;89(4):615-22. doi: 10.1016/S0029-7844(97)00059-8. Obstet Gynecol. 1997. PMID: 9083323 Clinical Trial.
OBJECTIVE: To evaluate the efficacy of a triphasic, combination oral contraceptive (OC), (norgestimate-ethinyl estradiol), in comparison with placebo in the treatment of moderate acne vulgaris. METHODS: Two hundred fifty women were enrolled in a multicenter, randomized, do …
OBJECTIVE: To evaluate the efficacy of a triphasic, combination oral contraceptive (OC), (norgestimate-ethinyl estradiol), in compari …
Evaluation of Potential Drug-Drug Interaction Between Delayed-Release Dimethyl Fumarate and a Commonly Used Oral Contraceptive (Norgestimate/Ethinyl Estradiol) in Healthy Women.
Zhu B, Nestorov I, Zhao G, Meka V, Leahy M, Kam J, Sheikh SI. Zhu B, et al. Clin Pharmacol Drug Dev. 2017 Nov;6(6):604-613. doi: 10.1002/cpdd.377. Epub 2017 Aug 7. Clin Pharmacol Drug Dev. 2017. PMID: 28783872 Free PMC article. Clinical Trial.
This 2-period crossover study was conducted to evaluate the potential for drug-drug interaction between DMF (240 mg twice daily) and a combined oral contraceptive (OC; norgestimate 250 mug, ethinyl estradiol 35 mug). Forty-six healthy women were enrolled; 32 completed the …
This 2-period crossover study was conducted to evaluate the potential for drug-drug interaction between DMF (240 mg twice daily) and a combi …
Effect of the coadministration of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate.
Bifano M, Sevinsky H, Hwang C, Kandoussi H, Jiang H, Grasela D, Bertz R. Bifano M, et al. Antivir Ther. 2014;19(5):511-9. doi: 10.3851/IMP2718. Epub 2013 Dec 17. Antivir Ther. 2014. PMID: 24343001 Clinical Trial.
The primary objective of this study was to assess the effect of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate (Ortho Tri-Cyclen()). METHODS: In this open-label single-sequence study, 20 healthy female sub …
The primary objective of this study was to assess the effect of daclatasvir on the pharmacokinetics of a combined oral contraceptive contain …
Cycle control with triphasic norgestimate and ethinyl estradiol, a new oral contraceptive agent.
Andolsek KM. Andolsek KM. Acta Obstet Gynecol Scand Suppl. 1992;156:22-6. doi: 10.3109/00016349209156511. Acta Obstet Gynecol Scand Suppl. 1992. PMID: 1324553 Clinical Trial.
Effective cycle control was demonstrated based on two multicenter, 2-year studies of the triphasic oral contraceptive (OC) agent containing the new progestin norgestimate. The estrogen in this OC is ethinyl estradiol. These open-label Phase III studies were conducted in th …
Effective cycle control was demonstrated based on two multicenter, 2-year studies of the triphasic oral contraceptive (OC) agent containing …
Clinical evaluation of a new triphasic oral contraceptive: norgestimate and ethinyl estradiol.
Gauthier A, Upmalis D, Dain MP. Gauthier A, et al. Acta Obstet Gynecol Scand Suppl. 1992;156:27-32. doi: 10.3109/00016349209156512. Acta Obstet Gynecol Scand Suppl. 1992. PMID: 1324554 Clinical Trial.
The safety and efficacy of the triphasic oral contraceptive agent containing norgestimate and ethinyl estradiol were evaluated in a 12-month study of 661 women. ...The safety and efficacy of the triphasic oral contraceptive (OC) containing norgestimate and ethinyl e …
The safety and efficacy of the triphasic oral contraceptive agent containing norgestimate and ethinyl estradiol were evaluated in a 1 …
Triphasic norgestimate-ethinyl estradiol for treating dysfunctional uterine bleeding.
Davis A, Godwin A, Lippman J, Olson W, Kafrissen M. Davis A, et al. Obstet Gynecol. 2000 Dec;96(6):913-20. doi: 10.1016/s0029-7844(00)01029-2. Obstet Gynecol. 2000. PMID: 11084177 Clinical Trial.
Abnormal bleeding patterns were reported by significantly fewer subjects receiving triphasic norgestimate-ethinyl E2 than in the placebo treatment group (P <. 001). Change from baseline in physical functioning (eg, self-care, walking, lifting, exercising) was significan …
Abnormal bleeding patterns were reported by significantly fewer subjects receiving triphasic norgestimate-ethinyl E2 than in the plac …
The duration of response to norgestimate and ethinyl estradiol in the treatment of acne vulgaris.
Olson WH, Lippman JS, Robisch DM. Olson WH, et al. Int J Fertil Womens Med. 1998 Nov-Dec;43(6):286-90. Int J Fertil Womens Med. 1998. PMID: 9920537 Clinical Trial.
Subjects received either 3 weeks of active OC treatment (i.e., 0.035 mg ethinyl estradiol plus increasing doses of norgestimate [0.180 mg, 0.215 mg, 0.250 mg]) and 1 week of inactive tablets, or 4 weeks of color-matched placebo tablets. ...CONCLUSION: A triphasic combinati …
Subjects received either 3 weeks of active OC treatment (i.e., 0.035 mg ethinyl estradiol plus increasing doses of norgestimate [0.18 …
The efficacy and tolerability of norgestimate/ethinyl estradiol (250 micrograms of norgestimate/35 micrograms of ethinyl estradiol): results of an open, multicenter study of 59,701 women.
Runnebaum B, Grunwald K, Rabe T. Runnebaum B, et al. Am J Obstet Gynecol. 1992 Jun;166(6 Pt 2):1963-8. doi: 10.1016/0002-9378(92)91396-r. Am J Obstet Gynecol. 1992. PMID: 1605286 Clinical Trial.
The efficacy and tolerability of a new oral contraceptive, norgestimate/ethinyl estradiol (250 micrograms of norgestimate/35 micrograms of ethinyl estradiol; Cilag GmbH Research, Sulzbach, Germany) were examined in an open-label study of 59,701 women who were evalua …
The efficacy and tolerability of a new oral contraceptive, norgestimate/ethinyl estradiol (250 micrograms of norgestimate/35 m …
Influence of alitretinoin on the pharmacokinetics of the oral contraceptive ethinyl estradiol/norgestimate.
Schmitt-Hoffmann AH, Roos B, Sauer J, Schleimer M, Schoetzau A, Leese PT, Weidekamm E, Maares J. Schmitt-Hoffmann AH, et al. Clin Exp Dermatol. 2011 Apr;36 Suppl 2:4-11. doi: 10.1111/j.1365-2230.2011.04031.x. Clin Exp Dermatol. 2011. PMID: 21443598 Clinical Trial.
Similarly, the influence of ethinyl estradiol/norgestimate on systemic exposure to alitretinoin and 4-oxo-alitretinoin was not clinically relevant. Alitretinoin was well tolerated when given either alone or with ethinyl estradiol/norgestimate. CONCLUSIONS: There was …
Similarly, the influence of ethinyl estradiol/norgestimate on systemic exposure to alitretinoin and 4-oxo-alitretinoin was not clinic …
130 results